Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

32 Publicaciones científicas disponibles

  • Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus

    4 de junio de 2019 | Revista: Frontiers in Immunology

    Soria-Juan B (1), Escacena N (2), Capilla-González V (2), Aguilera Y (2), Llanos L (1), Tejedo JR (2,3), Bedoya FJ (2,3), Juan V (4), De la Cuesta A (5), Ruiz-Salmerón R (6), Andreu E (7), Grochowicz L (7), Prósper F (7), Sánchez-Guijo F (8), Lozano FS (8), Miralles M (9), Del Río-Solá L (10), Castellanos G (11), Moraleda JM (11), Sackstein R (12), García-Arranz M 1, García-Olmo D (1), Martín F (2,3), Hmadcha A (2,3), Soria B (2,3); Collaborative Working Group “Noma Project Team”.

    (1) Fundación Jiménez Díaz Health Research Institute, Madrid, Spain.
    (2) Department of Regeneration and Cell Therapy, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Pablo de Olavide-University of Seville-CSIC, Seville, Spain.
    (3) Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.
    (4) Andalusian eHealth Library, Sevilla, Spain.
    (5) Unidad de Isquemia Crónica de Miembros Inferiores, Hospital Victoria Eugenia de la Cruz Roja, Sevilla, Spain.
    (6) Servicio de Cardiología, Hospital Universitario Virgen Macarena, Sevilla, Spain.
    (7) Clínica Universidad de Navarra, Pamplona, Spain.
    (8) IBSAL-Hospital Universitario Salamanca, Salamanca, Spain.
    (9) Department of Surgery, University of Valencia, Valencia, Spain.
    (10) Cirugía Vascular, Hospital Universitario de Valladolid, Valladolid, Spain.
    (11) Servicio Hematología y Hemoterapia, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
    (12) Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.


  • Inyección intraarticular de dos dosis diferentes de células madre mesenquimales de médula ósea autóloga versus ácido hialurónico en el tratamiento de la osteoartritis de rodilla

    31 de julio de 2018 | Revista: Journal of Translational Medicine

    Lamo-Espinosa JM (1,2), Mora G (1), Blanco JF (3), Granero-Moltó F (1,2), Núñez-Córdoba JM (4,5,6), López-Elío S (1), Andreu E (2), Sánchez-Guijo F (7), Aquerreta JD (8), Bondía JM (8), Valentí-Azcárate A (1), Del Consuelo Del Cañizo M (7), Villarón EM (7), Valentí-Nin JR (1), Prósper F (9,10).

    (1) Department of Orthopaedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Department of Traumatology, Complejo Hospitalario de Salamanca, Salamanca, Spain.
    (4) Division of Biostatistics, Research Support Service, Central Clinical Trials Unit, University of Navarra Clinic, Pamplona, Spain.
    (5) Department of Preventive Medicine and Public Health, Medical School, University of Navarra, Pamplona, Spain.
    (6) Epidemiology and Public Health Area, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
    (7) Department of Hematology, Complejo Hospitalario de Salamanca, Salamanca, Spain.
    (8) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Spain.
    (9) Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
    (10) Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain.


  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    12 de mayo de 2017 | Revista: Journal of Transational Medicine

    Inogés S (1,2), Tejada S (3), de Cerio AL (4,5), Pérez-Larraya JG (6), Espinós J (7), Idoate MA (8), Domínguez PD (9), de Eulate RG (9), Aristu J (10), Bendandi M (11,12), Pastor F (13), Alonso M (14), Andreu E (5), Cardoso FP (4,15), Valle RD (16). (1) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (2) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (3) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (4) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (5) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (6) Neurology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (7) Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (8) Pathology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (9) Radiology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (10) Radiation Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (11) Section on Hematology/Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University Baptist Healthcare Center, Winston-Salem, NC, USA.
    (12) Section of Hematology/Oncology, Department of Internal Medicine, W.G Hefner VA Medical Center, Salisbury/Charlotte, NC, USA.
    (13) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (14) Program in Solid Tumors and Biomarkers, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (15) Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (16) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain


  • Combined PI3K/Akt and Smad2 Activation Promotes Corneal Endothelial Cell Proliferation

    1 de febrero de 2017 | Revista: Investigative Ophthalmology and Visual Science

    Sabater AL (1), Andreu EJ (2), García-Guzmán M (2), López T (2), Abizanda G (2), Perez VL (3), Moreno-Montañés J (4), Prósper F (2). (1) Area of Cell Therapy, Clínica Universidad de Navarra, Pamplona, Navarra, Spain
    (2) Area of Cell Therapy, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (3) Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.
    (4) Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar